NOVO NORDISK A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 131.5 EUR | -2.41% |
|
0.00% | +43.76% |
| Sales 2024 * | 292B 42.4B 39.09B | Sales 2025 * | 353B 51.25B 47.24B | Capitalization | 4,320B 628B 579B |
|---|---|---|---|---|---|
| Net income 2024 * | 104B 15.13B 13.95B | Net income 2025 * | 128B 18.61B 17.16B | EV / Sales 2024 * | 14.9 x |
| Net Debt 2024 * | 22.53B 3.27B 3.02B | Net cash position 2025 * | 5.57B 810M 747M | EV / Sales 2025 * | 12.2 x |
| P/E ratio 2024 * |
42.1
x | P/E ratio 2025 * |
34.1
x | Employees | 66,015 |
| Yield 2024 * |
1.21% | Yield 2025 * |
1.49% | Free-Float | 70.22% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novo Nordisk A/S
More recommendations
More press releases
More news
| 1 day | -2.41% | ||
| 1 month | +2.70% | ||
| 3 months | +16.24% | ||
| 6 months | +38.30% | ||
| Current year | +43.76% |
1 week
128.06
135.48
1 month
128.06137.98
Current year
92.60137.98
1 year
68.14137.98
3 years
36.01137.98
5 years
21.01137.98
10 years
17.95137.98
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 90-12-31 | |
| Director of Finance/CFO | 53 | 98-12-31 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 15-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 62 | 15-03-18 |
Helge Lund
CHM | Chairman | 62 | 17-03-22 |
Martin MacKay
BRD | Director/Board Member | 68 | 18-02-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-27 | 134.7 | +0.27% | 251 |
| 24-07-05 | 131 | +0.51% | 156 |
| 24-07-04 | 130.3 | +1.76% | 516 |
| 24-07-03 | 128.1 | -3.01% | 769 |
| 24-07-02 | 132 | -2.80% | 735 |
End-of-day quote Wiener Boerse, June 27, 2024
More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
974
DKK
Average target price
952.2
DKK
Spread / Average Target
-2.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +56.89% | 823B | |
| -6.55% | 353B | |
| +15.99% | 320B | |
| +7.92% | 295B | |
| +13.96% | 239B | |
| +14.28% | 220B | |
| -0.49% | 219B | |
| +7.94% | 167B | |
| -2.57% | 159B |
- Stock Market
- Equities
- NOVO B Stock
- NNO2 Stock
